Day One公布2025年Ojemda™净产品收入初步预测 并提供2026年净产品收入指引

美股速递
Jan 12

生物制药公司Day One Biopharmaceuticals Inc.(以下简称Day One)今日公布了其核心产品Ojemda™在2025年的初步净产品收入预测,同时向市场提供了针对2026年的净产品收入指引。这一举措旨在向投资者和业界清晰展示公司对其重磅疗法未来商业表现的信心与预期。

Ojemda™作为公司研发管线中的关键资产,其收入预测是衡量公司未来增长潜力的重要指标。此次公布的指引不仅反映了市场对该产品的需求预期,也体现了公司在商业化执行方面的战略规划。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10